1. Pink Sheet
  2. >>Product Reviews
  3. >>Approvals

Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines

 
• By Emily Hayes

Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.

Amgen Inc. is set to launch the first FDA-approved oncolytic cancer vaccine Imylgic (T-VEC) in melanoma within a week, at an average cost of $65,000.

Pricing will vary depending on the patient and the company will “work with the health care community to implement a program that helps limit the average cost” to $65,000 for “eligible participating institutions,” the company said in a statement on Oct. 27 after the approval

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews

New EU Filings

 
• By Neena Brizmohun

Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

PharmaMar Seeks EU Fast-Track Status For ‘Practice-Changing’ ES-SCLC Therapy

 
• By Neena Brizmohun

PharmaMar, which wants to use the Jazz Pharmaceuticals-partnered drug, lurbinectedin, in combination with Roche’s Tecentriq for treating extensive-stage small cell lung cancer, is one of two companies that this month sought an accelerated assessment of their planned EU marketing applications.

US FDA Miss On Stealth’s Elamipretide Boosts Signal Of Broader Delays Due To Staff Cuts

 
• By Sue Sutter

Failing to meet the 29 April user fee date for the Barth syndrome treatment, and CDER’s request for a delay in responding to Vanda’s appeal of a tradipitant complete response letter, suggest a slowdown in review work due to layoffs and other recent changes.